We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Promethera Biosciences Treats First Patients with Promethera® HepaStem

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Promethera Biosciences has announced that it has treated its first two patients with its innovative treatment based on allogeneic adult liver stem cell technology (HepaStem).

These patients were treated and are followed at the Cliniques Universitaires Saint-Luc (Brussels, Belgium).

The trial, a prospective, open label multicenter phase I/II study testing Promethera® HepaStem is designed to evaluate the safety and the preliminary efficacy of Promethera® HepaStem in Urea Cycle Disorders and Crigler-Najjar Syndrome patients.

“We are delighted to have achieved this important milestone in HepaStem’s development” said Eric Halioua, co-founder and CEO of Promethera Biosciences.

“HepaStem is an innovation in the field of liver-based metabolic diseases,” said Dr. Beatrice De Vos, chief medical officer of Promethera Biosciences.

Dr. Vos continued, “This clinical trial will be the very first to apply allogeneic liver progenitor cells. This treatment with progenitor cells will contribute to restore a deficient enzyme function in Urea Cycle Diseases or in a Crigler-Najjar syndrome.”

The major innovation of Promethera® HepaStem resides in the simplicity of the treatment. This consists of a simple injection into the vein leading to the liver, which may make it possible to avoid radical and invasive surgery such as a liver transplant.

Promethera® HepaStem could be used to treat a wide variety of liver pathologies.

Thanks to the industrial development, if this therapy proves to be safe and effective, as many as a hundred patients could be treated from a single liver, thus largely overcoming the organ shortage problem.

"There is a real need for medical innovation to treat metabolic diseases in children; too many diseases are still intractable," said Professor Etienne Sokal, co-founder and chief scientific officer at Promethera Biosciences, paediatric hepatologist at Cliniques Universitaires St Luc and director of UCL's cell therapy research lab.

Professor Sokal continued, "This first study represents a major step in the development of Hepastem towards a therapy that could transform positively the prognosis of these diseases."